Denali Therapeutics
DNLI
114 hedge funds and large institutions have $1.49B invested in Denali Therapeutics in 2019 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 42 increasing their positions, 25 reducing their positions, and 21 closing their positions.
223% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $328K
68% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 25
2.42% more ownership
Funds ownership: 72.52% → 74.94% (+2.4%)
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
0% more funds holding
Funds holding: 114 → 114 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $1.6B → $1.49B (-$119M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$25.7M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$16.6M |
| 3 |
BlackRock
New York
|
+$13.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$6.98M |
| 5 |
CC
Casdin Capital
New York
|
+$6.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$20M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.94M |
| 4 |
LCG
Lisanti Capital Growth
New York
|
-$1.71M |
| 5 |
Squarepoint
New York
|
-$1.66M |
DNLI Hedge Fund Activity: Q2 2019 in Review
114 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2019, worth a combined $1.49B — down 7.4% from $1.6B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new DNLI positions and 21 closed out — a net gain of 2 holders — while 42 added to existing stakes and 25 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $25.7M. The largest seller was Fidelity International, cutting an estimated $20M.
- 114 institutional investors held Denali Therapeutics (DNLI) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $1.49B of Denali Therapeutics stock for Q2 2019, down 7.4% quarter-over-quarter.
- 23 funds opened new Denali Therapeutics positions in Q2 2019 and 21 closed out, a net change of +2 holders.
- The largest Denali Therapeutics buyer in Q2 2019 was Baillie Gifford & Co, an estimated $25.7M added.
- The largest Denali Therapeutics seller in Q2 2019 was Fidelity International, an estimated $20M sold.
Based on aggregated 13F filings for Q2 2019.